Evidence map›Paper›PMID 32988406›Full record

ArticleStem cell research & therapy2020

Time-dependent LPS exposure commands MSC immunoplasticity through TLR4 activation leading to opposite therapeutic outcome in EAE.

Mónica Kurte, Ana María Vega-Letter, Patricia Luz-Crawford, Farida Djouad, Danièle Noël, Maroun Khoury, Flavio Carrión

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Zinc sulfate modulates the C3H10T1/2 mesenchymal stem cell line secretome and NFκB signaling during inflammation to influence selected immune cell responses.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Impact of sepsis on bone marrow mesenchymal stem cells and its implications for hematopoiesis and immunosuppression.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Persistent tailoring of MSC activation through genetic priming.Molecular therapy. Methods & clinical development · 2024
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Mónica KurteLaboratorio de Inmunología Celular y Molecular, Centro de Investigación Biomédica, Universidad de Los Andes, Santiago, Chile.
Ana María Vega-LetterCells for Cells, Regenero, Av. Álvaro del Portillo 12.455, Las Condes, Santiago, Chile.
Patricia Luz-CrawfordLaboratorio de Inmunología Celular y Molecular, Centro de Investigación Biomédica, Universidad de Los Andes, Santiago, Chile.
Farida DjouadIRMB, Univ Montpellier, INSERM, Montpellier, France.
Danièle NoëlIRMB, Univ Montpellier, INSERM, Montpellier, France.
Maroun KhouryCells for Cells, Regenero, Av. Álvaro del Portillo 12.455, Las Condes, Santiago, Chile. mkhoury@uandes.cl.ORCID 0000-0002-9965-6266
Flavio CarriónPrograma de Inmunología Traslacional, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Av. Las Condes 12496 Lo Barnechea, Santiago, Chile. fcarrion@udd.cl.
Universidad de Los Andes, Chile · CLInserm · FRUniversidad del Desarrollo · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMesenchymal stem cells (MSCs) have been recognized for their regenerative and anti-inflammatory capacity which makes them very attractive to cell therapy, especially those ones to treat inflammatory and autoimmune disease. Two different immune-phenotypes have been described for MSCs depending on which Toll-like receptor (TLR) is activated. MSC1 is endowed with a pro-inflammatory phenotype following TLR4 activation with LPS. On the other hand, anti-inflammatory MSC2 is induced by the activation of TLR3 with Poly(I:C). High immunoplasticity of MSCs is a matter of concern in cell-based therapies. In this study, we investigated whether a single stimulus can induce both types of MSCs through a differential activation of TLR4 with LPS.

methodsMSCs were activated with LPS following a short exposure of 1-h (MSCs-LPS1h) or long-time exposure for 48 h (MSCs-LPS48h), and then, we evaluated the biological response in vitro, the immunosuppressive capacity of MSCs in vitro, and the therapeutic potential of MSCs in an experimental autoimmune encephalomyelitis (EAE) mouse model.

resultsOur results showed that 1-h LPS exposure induced a MSC1 phenotype. Indeed, MSCs-LPS1h expressed low levels of NO/iNOS and decreased immunosuppressive capacity in vitro without therapeutic effect in the EAE model. In contrast, MSCs-LPS48h achieved a MSC2-like phenotype with significant increase in the immunosuppressive capacity on T cell proliferation in vitro, together with an improved in the therapeutic effect and higher Treg, compared to unstimulated MSCs. Furthermore, we determine through the MSCs-TLR4KO that the expression of TLR4 receptor is essential for MSCs' suppressive activity since TLR4 deletion was associated with a diminished suppressive effect in vitro and a loss of therapeutic effect in vivo.

conclusionsWe demonstrate that MSCs display a high immunoplasticity commanded by a single stimulus, where LPS exposure time regulated the MSC suppressive effect leading into either an enhanced or an impairment therapeutic activity. Our results underscore the importance of phenotype conversion probably related to the TLR4 expression and activation, in the design of future clinical protocols to treat patients with inflammatory and autoimmune diseases.

Indexed as

Encephalomyelitis, Autoimmune, ExperimentalMesenchymal Stem CellsToll-Like Receptor 4AnimalsLipopolysaccharidesMiceTreatment OutcomeLipopolysaccharidesTlr4 protein, mouseToll-Like Receptor 4Autoimmune diseasesCell plasticityImmunosuppressionLPSMSCsTLR4

Identifiers

PMID32988406
PMCPMC7520958
OpenAlexW3088933438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.